These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32103681)

  • 21. Macular Atrophy Affecting Visual Outcomes in Patients Undergoing Anti-VEGF Treatment in Routine Clinical Practice.
    Rieveschl NB; Song W; Li A; Conti TF; Hom GL; Tsai GJ; Conti FF; Babiuch AS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2020 Feb; 51(2):68-75. PubMed ID: 32084278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Abdelfattah NS; Lei J; Shi Y; Marion KM; Morgenthien E; Gune S; Balasubramanian S
    Ophthalmology; 2020 Oct; 127(10):1360-1370. PubMed ID: 32402555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration.
    Abdolrahimzadeh S; Gharbiya M; Formisano M; Bertini F; Cerini A; Pacella E
    Curr Eye Res; 2019 Sep; 44(9):1000-1005. PubMed ID: 30999772
    [No Abstract]   [Full Text] [Related]  

  • 25. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
    Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION: Incidence and Characteristics.
    Bilgic A; Kodjikian L; Mathis T; Sudhalkar AA; Vasavada SA; Bhojwani DM
    Retina; 2021 Sep; 41(9):1901-1910. PubMed ID: 33411472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
    Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
    Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.
    Abdelfattah NS; Hariri AH; Al-Sheikh M; Pitetta S; Ebraheem A; Wykoff CC; Sadda SR;
    Am J Ophthalmol; 2018 Aug; 192():84-90. PubMed ID: 29763612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment.
    Kuroda Y; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Oishi A; Nakanishi H; Miyake M; Yoshikawa M; Yoshimura N
    Am J Ophthalmol; 2016 Jan; 161():94-103.e1. PubMed ID: 26432927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.
    Daien V; Nguyen V; Essex RW; Guymer R; Arnold JJ; Munk M; Ceklic L; Gillies MC; Barthelmes D;
    Br J Ophthalmol; 2020 Aug; 104(8):1064-1069. PubMed ID: 31843790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
    Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
    Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Abdelfattah NS; Zhang H; Boyer DS; Sadda SR
    Retina; 2016 Oct; 36(10):1843-50. PubMed ID: 27135213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
    Lee JY; Chung H; Kim HC
    Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Xu L; Mrejen S; Jung JJ; Gallego-Pinazo R; Thompson D; Marsiglia M; Freund KB
    Retina; 2015 Feb; 35(2):176-86. PubMed ID: 25387047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
    de Massougnes S; Dirani A; Mantel I
    Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Hikichi T; Agarie M
    Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):1088-1095. PubMed ID: 30901385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
    Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
    Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHOROIDAL IMAGING BIOMARKERS TO PREDICT HIGHLY RESPONSIVE AND RESISTANT CASES TREATED WITH STANDARDIZED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR REGIMEN IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Jhingan M; Cavichini M; Amador M; Dans K; Bartsch DU; Cheng L; Chhablani J; Freeman WR
    Retina; 2021 Oct; 41(10):2115-2121. PubMed ID: 34543243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.